Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis

Published:2020-06-04 Issue:6 Volume:15 Page:e0233571
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zheng Jiani,Wu Jingxun,Wang Chunyue,Zhuang Shiwen,Chen Jianbo,Ye Feng^ORCID

Funder

Cancer Hospital Foundation from the First Affiliated Hospital of Xiamen University

Youth Scientific Research Project of Fujian Provincial Health and Family Planning Commission

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;F Bray;CA: a cancer journal for clinicians,2018

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;N Howlader;J Natl Cancer Inst,2014

3. Breast cancer;N Harbeck;Lancet (London, England),2017

4. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger;F Cardoso;Ann Oncol,2018

5. Factors predicting late recurrence for estrogen receptor-positive breast cancer;I Sestak;J Natl Cancer Inst,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices;Future Oncology;2024-06-04

2. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN;Breast Cancer Research and Treatment;2024-04-01

3. The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials;Frontiers in Pharmacology;2024-01-15

4. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review;Journal of Cancer Research and Clinical Oncology;2024-01

5. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis;BMC Cancer;2023-08-31